Skip to Content
MilliporeSigma

Skip To

SML2628

NVP-BSK805 Trihydrochloride

≥98% (HPLC)

Synonym(s):

4-(2,6-Difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine trihydrochloride, 8-(3,5-Difluoro-4-morpholin-4-ylmethyl-phenyl)-2-(1-piperidin-4-yl-1H-pyrazol-4-yl)-quinoxaline trihydrochloride, 8-[3,5-Difluoro-4-(4-morpholinylmethyl)phenyl]-2-[1-(4-piperidinyl)-1H-pyrazol-4-yl]quinoxaline trihydrochloride, BSK 805 3HCl, BSK805, 3HCl, NVP-BSK 805 3HCl

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Size/SKUAvailabilityPrice
5 mg

Available to ship TODAYfromMILWAUKEE

$81.20
$69.02
25 mg

Available to ship TODAYfromMILWAUKEE

$328.00
$278.80

About This Item

Empirical Formula (Hill Notation):
C27H28F2N6O·3HCl
CAS Number:
Molecular Weight:
599.93
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder

$69.02

List Price$81.20Save 15%
Web-Only Promotion

Available to ship TODAYDetails


Request a Custom Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

≥98% (HPLC)

form

powder

color

faint yellow to dark orange

solubility

H2O: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

Fc1c(c(cc(c1)c3c4nc(cnc4ccc3)c5c[n](nc5)C6CCNCC6)F)CN2CCOCC2

InChI

1S/C27H28F2N6O/c28-23-12-18(13-24(29)22(23)17-34-8-10-36-11-9-34)21-2-1-3-25-27(21)33-26(15-31-25)19-14-32-35(16-19)20-4-6-30-7-5-20/h1-3,12-16,20,30H,4-11,17H2

InChI key

IBPVXAOOVUAOKJ-UHFFFAOYSA-N

Biochem/physiol Actions

NVP-BSK805 is a selective, ATP-competitive (Ki = 0.43 nM) Janus kinase 2 (JAK2) inhibitor (IC50 = 0.58 and 0.56 nM against full-length wild-type and V617F JAK2, respectively) with greatly reduced potency against TYK2, JAK3, JAK1 (IC50 = 10.76, 18.68, 31.63 nM against respective JAK homology domain 1) and >300-fold selectivity over a panel of 36 other kinases. BSK805 potently inhibits STAT5 phosphorylation (by >90% at 100 nM; MB-02 & SET-2 cells) and proliferation in JAK2V617F mutant cultures in vitro (GI50= 39-331 nM; 75% SET-2 growth inhibition at 150 nM) and in Ba/F3 JAK2V617F-bearing mice in vivo (150 mg/kg p.o.). BSK805 daily oral administration is also efficacious against rhEpo-induced splenomegaly and polycythemia in mice (50-100 mg/kg) and rats (25-50 mg/kg) with good pharmacokinetics and oral avilability.
Orally available, ATP-competitive Janus kinase 2 (JAK2) inhibitor with efficacy against JAK2V617F-driven leukemic disease in mice and rats in vivo.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML2154S9070SML1788
description

≥98% (HPLC)

description

≥98% (HPLC)

description

≥98% (HPLC), solid

description

≥98% (HPLC)

form

powder

form

powder

form

solid

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

-

storage temp.

−20°C

solubility

H2O: 2 mg/mL, clear

solubility

H2O: 2 mg/mL, clear

solubility

H2O: 22 mg/mL

solubility

DMSO: 5 mg/mL, clear (warmed)

color

faint yellow to dark orange

color

white to beige

color

white

color

white to beige


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Questions

Reviews

No rating value

Active Filters